Crossmark

FocaL mass drug administration for Plasmodium vivax malaria elimination (FLAME): study protocol for an open-label cluster randomized controlled trial in Peru

Crossref DOI link: https://doi.org/10.1186/s13063-025-09112-1

Published Online: 2025-10-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fine, Sydney R. https://orcid.org/0000-0003-2700-9489
Soto Calle, Veronica

Altamirano Quiroz, Astrid

Rodriquez Ferruci, Hugo

Manrique, Paulo

Wu, Xue

Carrasco Escobar, Gabriel

Benjamin-Chung, Jade

Bennett, Adam

Auburn, Sarah

Price, Ric N.

Greenhouse, Bryan

Baird, J. Kevin

Domingo, Gonzalo J.

Roh, Michelle E.

Rosas, Angel

Llanos-Cuentas, Alejandro

Hsiang, Michelle S.
Funding

Funding for this research was provided by:

National Institute of Allergy and Infectious Diseases (U01AI157962)
License Information

Text and Data Mining valid from 2025-10-14

Version of Record valid from 2025-10-14
More Information

Article History

Received: 6 December 2024

Accepted: 28 August 2025

First Online: 14 October 2025

Declarations

:

: This study protocol has been approved by National Institute of Health (INS) in Peru, Universidad Peruana Cayetano Heredia Institutional Review Board, and by University of California San Francisco Institutional Review Board. The trial is registered at clinicaltrials.gov (NCT05690841). Consent will be obtained from all study participants prior to conduct of any study activities.

: Not applicable

: All authors declare no competing interests. Jade Benjamin-Chung is a Chan Zuckerberg Biohub Investigator.

Document is current

Any future updates will be listed below